The clinical relevance of such observations is supported by the demonstration that the levels of BRD4 in tumor-associated macrophages and PAI-1 in tumors are elevated in CRC patients with chemoresistance and correlate with shorter recurrence-free survival (Pan et al., 2025). This evidence concerns the gene BRD4 and neoplasm.